))
Poster Pearl: Dato-DXd Demonstrates Intracranial Efficacy in NSCLC
Manage episode 439677504 series 3600068
内容由ReachMD提供。所有播客内容（包括剧集、图形和播客描述）均由 ReachMD 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
…
continue reading
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
9集单集
分享
